Treatment Approach for Prostate Cancer with Possible Metastases

Disease Assessment and Staging

• The patient's presentation suggests metastatic disease based on CT findings showing possible lung and liver metastases, which would upstage the cancer from the initial Stage 2 classification, according to the Annals of Oncology 1
• A PSA level of 20 ng/mL places the patient in the high-risk category, even without considering the metastatic findings, as stated by Praxis Medical Insights 2
• Confirmation of metastases is essential, as treatment approach differs significantly between localized and metastatic disease, as noted by Praxis Medical Insights 2
• A bone scan should be performed to evaluate for bone metastases, which are common in metastatic prostate cancer, recommended by both the Annals of Oncology and the Journal of the National Comprehensive Cancer Network 1, 3

Treatment Recommendations for Metastatic Disease

• Androgen deprivation therapy (ADT) is the standard first-line treatment for metastatic prostate cancer, administered either through surgical castration or medical castration using LHRH agonists, as recommended by Praxis Medical Insights 4, 5
• When starting treatment with an LHRH agonist, an antiandrogen should be given for 3-4 weeks initially to prevent testosterone flare, according to Praxis Medical Insights 4, 5
• Continuous ADT is recommended over intermittent ADT for metastatic hormone-naïve prostate cancer, as stated by Praxis Medical Insights 4
• For patients fit enough for chemotherapy, adding docetaxel to ADT has shown survival benefits in metastatic hormone-sensitive prostate cancer, as noted by Praxis Medical Insights 5

Monitoring and Follow-up

• Regular monitoring should include clinical assessment, PSA measurement, and management of treatment side effects, as recommended by Praxis Medical Insights 5
• Initial imaging by bone scan and CT scan (or MRI) of the abdomen and pelvis is strongly recommended, according to Praxis Medical Insights 5
• Men on long-term ADT should be monitored for side effects including osteoporosis and metabolic syndrome, as stated by Praxis Medical Insights 5
• Regular exercise should be recommended as it reduces fatigue and improves quality of life in men on ADT, as noted by Praxis Medical Insights 4, 5

Treatment for Disease Progression

• If the disease progresses to castration-resistant prostate cancer (CRPC), additional treatment options include abiraterone or enzalutamide for asymptomatic/mildly symptomatic patients, as recommended by Praxis Medical Insights 4, 5
• Docetaxel chemotherapy is an option for symptomatic patients with good performance status, as noted by Praxis Medical Insights 4, 5
• Radium-223 is an option for patients with bone-predominant, symptomatic metastatic CRPC without visceral metastases, as stated by Praxis Medical Insights 5

Important Considerations and Caveats

• PSA is not always a reliable indicator of disease activity in patients with undifferentiated metastatic prostate cancer with neuroendocrine features, as noted by Praxis Medical Insights 5
• Combined androgen blockade (CAB) may provide a small survival benefit but with increased toxicity, as stated by Praxis Medical Insights 4
• Supportive care for bone metastases may include external beam radiotherapy for palliation of painful bone metastases and denosumab or zoledronic acid to prevent skeletal-related events, as recommended by Praxis Medical Insights 5

Management and Prognostic Factors in Metastatic Hormone‑Sensitive Prostate Cancer

ADT Initiation

• Bilateral orchiectomy and luteinizing‑hormone‑releasing hormone (LHRH) agonists achieve equivalent rates of castration in men with metastatic prostate cancer, according to the American Society of Clinical Oncology (ASCO) evidence. 6
• When LHRH agonists are used, a short course (3–4 weeks) of an anti‑androgen should be added to prevent testosterone flare, as recommended by the NCCN guidelines. 7
• Long‑term continuous ADT is preferred over intermittent schedules for patients with metastatic disease (NCCN). 7

Bone‑Targeted Support

• Zoledronic acid administered every 3–4 weeks reduces skeletal‑related events in patients with bone metastases, per NCCN recommendations. 7

Combination Systemic Therapy

• Adding an androgen‑receptor pathway inhibitor (abiraterone or enzalutamide) to ADT improves overall survival by roughly 30–40 % compared with ADT alone (NCCN). 7
• For fit patients with high‑volume disease (defined as visceral metastases or ≥4 bone lesions with at least one outside the axial skeleton), docetaxel chemotherapy should be combined with ADT, as advised by NCCN. 7

Prognostic Factors

Monitoring Parameters

• A complete biochemical response is defined by an undetectable PSA, although this is uncommon in metastatic settings (British Journal of Cancer). 8
• In localized disease, the median interval from PSA rise to development of metastases is about 8 years; once metastases are established, progression to death averages ~5 years, varying by metastatic site (British Journal of Cancer). 8

Treatment‑Related Pitfalls

• PSA alone is unreliable in neuroendocrine‑differentiated tumors (high Gleason grades); tissue biopsy of accessible lesions is recommended when ADT response is inadequate (NCCN). 7
• Visceral metastases warrant escalation to more aggressive systemic regimens and consideration of clinical‑trial enrollment (NCCN).
• Long‑term ADT can cause osteoporosis, metabolic syndrome, and cardiovascular complications; routine monitoring and preventive measures are advised (ASCO). 6
• A rising PSA during docetaxel therapy does not alone define treatment failure; continuation is appropriate in the absence of clinical progression (NCCN). 7

Palliative Radiation

• External‑beam radiation should be employed for relief of painful bone metastases (NCCN). 7